JERUSALEM, Jan. 06, 2026 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced the release of final results from its first-in-human pancreatic cancer study in Montreal, Canada exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC). The results have been published as two abstracts and will be presented at the upcoming 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, January 8 – 10, 2026.
Study Principal Investigator Corey Miller, MD, MSc, Director of Therapeutic Endoscopy of the Division of Gastroenterology of the JGH, Assistant Professor of Medicine at McGill University, Associate Researcher at the Lady Davis Institute, will lead a presentation entitled “Feasibility, Safety and Efficacy of Endoscopic Ultrasound-Guided Alpha Radiotherapy for Advanced Pancreatic Cancer: A Pilot Study” with final clinical results of the Company’s trial. In the trial, 32 patients with Stage II, III or IV PDAC were treated, many of whom had one or more prior rounds of chemotherapy. The results demonstrate a 22% objective response rate (ORR) and an 81% disease control rate (DCR) across all 32 patients treated in the study, or 23% ORR and 87% DCR when excluding the first two patients, who were deliberately given low dosages in order to examine feasibility and safety only.
The Company is further exploring the use of Alpha DaRT in treating PDAC in its U.S. multi-center pancreatic cancer pilot study, known as IMPACT (Intratumoral Pancreatic Alpha Combination Trial), evaluating the safety, feasibility, and efficacy of Alpha DaRT in combination with chemotherapy for patients with newly diagnosed unresectable locally advanced or metastatic pancreatic adenocarcinoma, as well as in other clinical studies in Europe. Additional information about the IMPACT trial can be found at https://clinicaltrials.gov/study/NCT06698458.
“We are very excited about the results of the study, in which we were the first clinicians to deliver Alpha DaRT via endoscopic ultrasound into the pancreas,” added Dr. Miller. “The results indicate that Alpha DaRT is a technically feasible treatment of pancreatic cancer, with a strong safety profile and encouraging local disease control. We look forward to further exploration of the use of Alpha DaRT for PDAC patients in the IMPACT trial as well as future trials, with the potential to generate a meaningful data set focused on a specific patient population with newly diagnosed disease.”
In addition, in a presentation entitled “Inflammatory and Immune Marker Dynamics following Intratumoral Alpha DaRT for Pancreatic Cancer”, Kim Anh Ma, MD, Assistant Professor of Oncology at Jewish General Hospital in Montreal, will present results showing the immune-preserving profile of Alpha DaRT in PDAC, based on immune markers as well as inflammatory indices known to be negative prognostic indicators, and which typically worsen after other forms of radiation therapy. In a study of 23 PDAC patients treated with Alpha DaRT who had complete laboratory data, one month following Alpha DaRT treatment, investigators observed no significant change in Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, CD4/CD8 T-cell ratio, or C-Reactive Protein levels, demonstrating immune system preservation not typical of conventional radiation therapy treatments. Moreover, low post-treatment levels of some of these indices were associated with favorable disease control. Furthermore, a dramatic drop in levels of IL-6 cytokine (p<0.000001), a key mediator of inflammation, suggested a potential reduced inflammatory effect.
Dr. Ma noted, “It is quite unique to find a radiation therapy with reduced inflammatory profile and no observed increase in negative prognostic factors, typically linked to radiation-induced lymphopenia. This may enable, or even support, other systemic therapies, such as immunotherapy, and may also help explain anecdotes where systemic response to chemotherapy appeared to improve after insertion of Alpha DaRT into the primary tumor in the pancreas.”
Uzi Sofer, CEO of Alpha Tau, stated, “Exploring the treatment of pancreatic cancer remains a cornerstone of our strategy for Alpha DaRT, with multiple clinical trials being pursued in parallel, led by our flagship IMPACT trial, which continues to see an excellent pace of recruitment. We look forward to generating further data in this indication in 2026 and forging ahead toward a potential future approval in this key indication.”